Spire Healthcare Group (LON:SPI) Rating Reaffirmed
The financial company has just set a target PPS of GBX 310.00 on Spire Healthcare Group (LON:SPI) shares. This is 1.57% from the price per share. In a comprehensive report revealed to clients on Tuesday morning, JP Morgan Cazenove reconfirmed their Neutral rating on shares of SPI.
From a total of 7 analysts covering Spire Healthcare Group (LON:SPI) stock, 3 rate it a ”Buy”, 0 a “Sell”, and 4 a ”Hold”. This means that 43% of the ratings are positive. The highest target price is GBX 80 while the lowest target price is GBX 27. The mean of all analyst targets is GBX 57.14 with a 6.38% above today’s (GBX 305.2) stock price. Spire Healthcare Group was the topic of 24 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Investec downgraded shares on December 3 to “Sell” rating. JP Morgan downgraded shares to “Neutral” rating and GBX 310 target share price in a report from a November 12. Barclays Capital maintained SPI stock in a recent report from November 25 with “Overweight” rating. Numis Securities maintained the rating on August 21. Numis Securities has a “Add” rating and a GBX 390 price target on shares. Finally, Jefferies downgraded the stock to “Hold” rating in a report issued on a November 16.
The stock closed the day at GBX 305.2 during the previous session. It is down 12.65% since May 11, 2015 and is downtrending. It has underperformed by 11.57% the S&P500.
Spire Healthcare Group plc is a United Kingdom independent hospital group offering a range of integrated surgical, medical and diagnostic services. The company has a market cap of 1.19 billion GBP. The Firm provides in-patient, daycase and out-patient care from approximately 39 hospitals, around 13 clinics and one specialist care center across England, Wales and Scotland. It has 23.57 P/E ratio. The Firm also owns and operates a sports medicine, physiotherapy and rehabilitation brand, Perform; a screening service, Lifescan, as well as national pathology services.